Dr. Agarwala on the Role of Cytokines in the Immunotherapy Landscape

Video

Sanjiv S. Agarwala, MD, Chief of Medical Oncology, Hematology, St. Luke's Cancer Center and Temple University, discusses the differences between cytokines and other types of immunotherapies.

Sanjiv S. Agarwala, MD, Chief of Medical Oncology, Hematology, St. Luke's Cancer Center and Temple University, discusses the differences between cytokines and other types of immunotherapies.

Cytokines and newer immunotherapies such as checkpoint inhibitors have almost opposite mechanisms of action, explains Agarwala. Cytokines get the immune system going, while checkpoint inhibitors prevent the immune system’s natural breaks from kicking in. Taking the breaks off the immune system with drugs like checkpoint inhibitors clinically seems to be a more effective method, says Agarwala.

However, there may be benefit from combinations therapies that include both checkpoint inhibitors and cytokines, he says. Ongoing studies are examining the combination of pegylated interferon and pembrolizumab in melanoma.

Related Videos
Mike Lattanzi, MD, medical oncologist, Texas Oncology
Vikram M. Narayan, MD, assistant professor, Department of Urology, Emory University School of Medicine, Winship Cancer Institute; director, Urologic Oncology, Grady Memorial Hospital
Stephen V. Liu, MD
S. Vincent Rajkumar, MD
Pashtoon Murtaza Kasi, MD, MS
Naseema Gangat, MBBS
Samilia Obeng-Gyasi, MD, MPH,
Kian-Huat Lim, MD, PhD
Saurabh Dahiya, MD, FACP, associate professor, medicine (blood and marrow transplantation and cellular therapy), Stanford University School of Medicine, clinical director, Cancer Cell Therapy, Stanford BMT and Cell Therapy Division
Muhamed Baljevic, MD